Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Nanoform Finland Plc - Manager's Transactions - Peter Hänninen

Nanoform Finland
Download the release

Company release

Nanoform Finland Plc

December 18, 2024

17.01 Finnish time / 16.01 Swedish time

Nanoform Finland Plc - Manager's Transactions - Peter Hänninen

Helsinki, Finland - Manager's transaction related to Nanoform Finland Plc's General Counsel and Chief Development Officer Peter Hänninen's acceptance of stock options of Nanoform Finland Plc:

Nanoform Finland Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Peter Hänninen

Position: Other senior manager

Issuer: Nanoform Finland Oyj

LEI: 743700JJO2NU8LBS1592

Notification type: INITIAL NOTIFICATION

Reference number: 88273/4/4

____________________________________________

Transaction date: 2024-12-17

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: Nanoform Finland Oyj stock option 1/2025

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 150000 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 150000 Volume weighted average price: 0 EUR

For further information, please contact:

Albert Haeggström, CFO

albert.haeggstrom@nanoform.com

+358 29 370 0150

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com

+46 7686 650 11

About Nanoform

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Carnegie Investment Bank AB (publ), +46 8-588 68 570 For more information, please visit www.nanoform.com.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team